For-Profit SMO Expansion Into Pediatrics Is Limited; Focus Is On Niche Groups
For-profit site management organizations are likely to continue to concentrate on profitable pediatric populations and not expand into a wider variety of pediatric disease study areas in the near term, Pediatric Clinical Trials International CEO John Niles told a Drug Information Association workshop April 3.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth